Article information
Objetivo
Estudiar la relación entre las concentraciones séricas de lipoproteína(a) y el fenotipo de apolipoproteína(a) en un grupo de varones con síndrome coronario agudo.
Pacientes y métodoSe determinaron las concentraciones séricas de lipoproteína(a) y el fenotipo de apolipoproteína(a) a 22 varones de entre 30 y 80 años con síndrome coronario agudo,al ingreso y al mes de evolución.
ResultadosLos varones con un síndrome coronario agudo muestran una frecuencia elevada de fenotipos de apolipoproteína(a) de tamaño pequeño y concentraciones más elevadas de lipoproteína(a).
ConclusionesEl fenotipo de apolipoproteína(a) puede desempeñar un papel adicional en la etiología de la enfermedad arterial coronaria.
Palabras clave:
Lipoproteína(a)
Apolipoproteínas
Enfermedad coronaria
Objective
To study the relationship between the plasma concentrations of lipoprotein(a) and apolipoprotein(a) phenotype in a group of males with acute coronary syndromes.
Patients and methodPlasma lipoprotein(a) concentrations and apolipoprotein(a) phenotype were determined in twenty-two males aged thirty to eighty years with acute coronary syndrome on admission and at one month of follow-up.
ResultsPatients with acute coronary syndrome showed a high frequency of small-sized apolipoprotein(a) phenotypes and higher lipoprotein(a) concentrations.
ConclusionsApolipoprotein(a) phenotype may play an additional role in the etiology of coronary artery disease.
Key words:
Lipoprotein(a)
Apolipoproteins
Coronary heart disease
Full text is only aviable in PDF
Bibliografía
[2.]
G. Utterman, H.J. Menzel, H.G. Kraft, H.C. Duba, H.G. Kemmler, C. Seiyz.
Lipoprotein(a) glycoprotein phenotypes. inheritance and relation to lp(a)-lipoprotein concentrations in plasma.
J Clin Invest, 80 (1987), pp. 458-465
[3.]
C. Lackner, J.C. Cohen, H. Hobbs.
Molecular definition of the extreme size polymorphism in apolipoprotein(a).
Hum Mol Gen, 2 (1993), pp. 933-940
[4.]
E. Boerwinkle, H.J. Menzel, H.G. Kraft.
Genetics of the quantitative lp(a) lipoprotein trait.
Hum Genet, 82 (1989), pp. 73-78
[5.]
G. Uterman, C. Duba, H.J. Menzel.
Genetics of the quantitative lp(a) lipoprotein trait. II: inherence of lp(a) glycoprotein phenotypes.
Hum Genet, 78 (1988), pp. 47-50
[6.]
E. Boerwinkle, C.C. Leffert, J. Lin, C. Lackner, G. Chiesa, H.H. Hobbs.
Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations.
J Clin Invest, 90 (1992), pp. 52-60
[7.]
M. Seed, F. Hoppichler, D. Reaveley, S. McCarthy, G.R. Thompson, E. Boerwinkle, et al.
Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia.
N Engl J Med, 322 (1990), pp. 1494-1499
[8.]
J.D. Kark, C. Sandholzer, Y. Friedlander, G. Uterman.
Plasma lp(a), apolipoprotein(a) isoforms and acute myocardial infarction in men and women: a case-control study in the jerusalem population.
Atherosclerosis, 98 (1993), pp. 139-151
[9.]
J.W. Gaubatz, R.C. Hoogeven, A.S. Hoffman, K.G. Ghazzaly, H.J. Pownall, J. Jr Guevara, et al.
Isolation, quantitation, and characterization of stable complex formed by lp(a) binding to triglyceride-rich lipoproteins.
J Lipid Res, 42 (2001), pp. 2058-2068
[10.]
G.M. Kostner, P. Avogaro, G. Cazzolato, E. Marth, G. Bittolo-Bon, G.B. Qunici.
Lipoprotein lp(a) and the risk of myocardial infarction.
Atherosclerosis, 38 (1981), pp. 51-61
[11.]
J. Jr Genest, J.L. Jenner, J.R. McNamara, J.M. Ordovas, S.R. Silberman, P.W.F. Wilson, et al.
Lipoprotein cholesterol, apolipoprotein a-i and b and lipoprotein(a) abnormalities in men with premature coronary artery disease.
J Am Coll Cardiol, 19 (1992), pp. 792-802
[12.]
G.C. Rhoads, G. Dahlen, K. Berg, E.N. Morton, A.L. Dannenberg.
Lp(a) lipoprotein as a risk factor for myocardial infarction.
JAMA, 256 (1986), pp. 2540-2544
[13.]
M. Bihari-Varga, G. Kostner, A. Czinner.
Lp(a) and the risk of coronary heart disease.
Eur J Epidemiol, 8 (1992), pp. 33-35
[14.]
J.W. McLean, J.E. Tomlinson, W.J. Kuang.
CDNA sequence of human apolipoprotein(a) is homologous to plasminogen.
Nature, 330 (1987), pp. 132-137
[15.]
K.A. Hajjar, D. Gavish, J.L. Breslow, R.L. Nachman.
Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis.
Nature, 339 (1989), pp. 303-305
[16.]
L.A. Miles, G.A. Fless, F.G. Levin, A.M. Scanu, E.F. Flow.
A potential basis for the trombotic risk associated with lipoprotein(a).
Nature, 339 (1989), pp. 301-303
[17.]
D.I. Simon, G.M. Fless, A.M. Scanu.
Tissue type plasminogen activator binds to and is inhibited by surface-bound lp(a) and LDL.
Biochemistry, 30 (1991), pp. 6671-6677
[18.]
J.M. Edelberg, C.F. Reilly, S.V. Pizzo.
The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1. the effects of fibrinogen, heparin vitronectin and lipoprotein(a).
J Biol Chem, 266 (1991), pp. 7488-7493
[19.]
M.J. Chapman, T. Huby, F. Nigon, J. Thillet.
Lipoprotein(a): implication in atherothrombosis.
Atherosclerosis, 110 (1994), pp. 69-75
[20.]
A.M. Scanu, G.M. Fless.
Lp(a) heterogeneity and biological relevance.
J Clin Invest, 85 (1990), pp. 1709-1715
[21.]
J.C. Cohen, G. Chiesa, H.H. Hobbs.
Sequence polymorphisms in the apolipoprotein(a) gene. evidence for dissociation between apolipoprotein(a) size and plasma lipoprotein(a) levels.
J Clin Invest, 91 (1993), pp. 1630-1636
[22.]
J. Pedro-Botet, M. Sentí, J. Rubiés-Prat, T. Auguet, J. Marrugat.
Relación entre concentración sérica de lipoproteína(a), polimorfismo genético de la apolipoproteína(a) e historia familiar de arteriosclerosis.
Clin Invest Arterioscl, 7 (1995), pp. 144-149
[23.]
C. Sandholzer, D.M. Hallman, M. Saha, G. Sigurdsson, C. Lackner, A. Csaszar, et al.
Effects of the apolipoprotein(a) size polymorphism on the lp(a) concentration in 7 ethnic groups.
Hum Genet, 86 (1991), pp. 607-614
[24.]
S. Islam, B. Gutin, C. Smith, F. Treiber, M.I. Kamboh.
Association of apolipoprotein(a) phenotypes in children with family history of premature coronary artery disease.
Arterioscler Thromb, 14 (1994), pp. 1609-1616
[25.]
S. Martín, J. Pedro-Botet, J. Joven, J.M. Simó, M.G. Ladona, M. Pavesa, et al.
Heterozygous apolipoprotein(a) status and protein expression as a risk factor for premature coronary heart disease.
J Lab Clin Med, 139 (2002), pp. 181-187
[26.]
R. Carmena, S. Lussier-Cacan, M. Roy, A. Minnich, A. Lirgenhel, F. Kronenberg, et al.
Lp(a) levels and atherosclerotic vascular disease in a sample of patients with familial hypercholesterolemia sharing the same gene defect.
Arteriocler Thromb, 16 (1996), pp. 129-136
Copyright © 2003. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.